SENSI, ELISA
 Distribuzione geografica
Continente #
NA - Nord America 620
EU - Europa 340
AS - Asia 118
AF - Africa 30
SA - Sud America 4
Totale 1.112
Nazione #
US - Stati Uniti d'America 608
DE - Germania 94
IT - Italia 80
SE - Svezia 51
SG - Singapore 41
AT - Austria 39
CN - Cina 39
BG - Bulgaria 31
GB - Regno Unito 27
VN - Vietnam 21
CI - Costa d'Avorio 14
CA - Canada 12
SN - Senegal 12
FI - Finlandia 9
IN - India 7
HK - Hong Kong 6
BR - Brasile 4
KR - Corea 4
NG - Nigeria 3
RU - Federazione Russa 3
FR - Francia 2
EE - Estonia 1
EG - Egitto 1
PL - Polonia 1
PT - Portogallo 1
RO - Romania 1
Totale 1.112
Città #
Chandler 87
Fairfield 76
Woodbridge 63
Ann Arbor 49
Houston 45
Ashburn 41
Seattle 38
Vienna 37
Sofia 31
Cambridge 30
Wilmington 28
Serra 17
Singapore 16
Abidjan 14
Pisa 14
Princeton 14
Beijing 13
Bremen 13
Boardman 12
Dakar 12
Lawrence 12
New York 12
Dong Ket 11
Medford 11
Dearborn 10
Florence 10
Ottawa 10
Des Moines 8
Lancaster 8
London 7
Hong Kong 6
Lucca 5
Frankfurt am Main 4
Lappeenranta 4
Nanjing 4
Ogden 4
Bologna 3
Daejeon 3
Hebei 3
Lagos 3
Marseille 2
Milan 2
Phoenix 2
Positano 2
Pune 2
San Diego 2
San Francisco 2
Seacroft 2
Shenzhen 2
Augusta 1
Cairo 1
Capannori 1
Chengdu 1
Chicago 1
Chiswick 1
Clearwater 1
Düsseldorf 1
Easton 1
Fuzhou 1
Gallarate 1
Guangzhou 1
Haikou 1
Hangzhou 1
Hefei 1
Jiaxing 1
Lugo 1
Montreal 1
Nürnberg 1
Redwood City 1
Santa Clara 1
Seoul 1
Shanghai 1
Shenyang 1
Tallinn 1
Tianjin 1
Toronto 1
Trieste 1
Vicopisano 1
Warsaw 1
Totale 836
Nome #
Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines 178
Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer 147
The Molecular Signature More Than the Site of Localization Defines the Origin of the Malignancy 105
Advantages and disadvantages of prophylactic central compartment lymph node dissection for differentiated thyroid cancer: the first randomized controlled study from a single referral center. 102
ALK rearrangement in a large series of consecutive non-small cell lung cancers: Comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment 93
Clinical Impact of Pretreatment EGFR T790M Mutation in Lung Adenocarcinoma Patients 84
null 78
Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36 months. 77
Primary Tumor Sidedness and Benefit from FOLFOXIRI plus Bevacizumab as Initial Therapy for Metastatic Colorectal Cancer 76
Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial 75
Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer 62
Feasibility of BRCA1/2 testing of formalin-fixed and paraffin-embedded pancreatic tumor samples: A consecutive clinical series 50
Immunohistochemistry is highly sensitive and specific for the detection of NRASQ61R mutation in melanoma 16
Totale 1.143
Categoria #
all - tutte 3.715
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.715


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020190 0 0 0 13 30 25 32 22 21 20 22 5
2020/2021101 7 5 13 3 1 9 6 2 18 9 4 24
2021/2022126 2 5 0 2 24 25 1 7 7 9 4 40
2022/2023275 23 49 19 35 34 28 0 17 51 2 15 2
2023/2024103 9 7 16 4 10 20 8 7 2 3 5 12
2024/202533 2 13 3 15 0 0 0 0 0 0 0 0
Totale 1.143